CellaVision AB engages in the provision of digital microscopy solutions for hematology laboratories. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
How did CVLLY's recent EPS compare to expectations?
The most recent EPS for CellaVision AB is $0.94, not beating expectations of $1.57.
How did CellaVision AB CVLLY's revenue perform in the last quarter?
CellaVision AB revenue for the last quarter is $0.94
What is the revenue estimate for CellaVision AB?
According to 5 of Wall street analyst, the revenue estimate of CellaVision AB range from $206.85M to $174.44M
What's the earning quality score for CellaVision AB?
CellaVision AB has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does CellaVision AB report earnings?
CellaVision AB next earnings report is expected in 2026-07-23
What are CellaVision AB's expected earnings?
CellaVision AB expected earnings is $196.75M, according to wall-street analysts.
Did CellaVision AB beat earnings expectations?
CellaVision AB recent earnings of $166.42M does not beat expectations.